Pulmonx Corporation

NASDAQ:LUNG

Medical - Devices

Healthcare
$2.69 +3.60%

+$0.05 today

Market cap
$117.15M
Beta
0.28
P/E (TTM)
-1.0
EPS (TTM)
-$1.27
52W Low $1.13High $3.88

Volume 0.48M

Average 0.44M

LUNG Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Pulmonx CorporationNASDAQ: LUNG

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 77.9%

Gross margin was 77.9% in Q1 FY2026, up 5.4 pp from a year earlier. On a trailing-twelve-month basis it was 75.5%, up 2.0 pp year over year. Over 3 fiscal years it narrowed by 0.1 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
77.9%+0.3 pp QoQ
Last fiscal yearDec 2025
74.2%+0.2 pp YoY
LTMMar 2026
75.5%+2.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+5.4 pp——
1 year+0.2 pp——
3 years-0.1 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
74.2%
Year-over-year change
+0.2pp

Gross Margin vs competitors

How LUNG compares with its peers on the latest reported figures

  • LUNG's LTM Mar 2026 gross margin of 75.5% is the 3rd highest of the 6 companies compared; the peer median is 67.8%.
  • Its year-over-year change of +2.0 pp is the 2nd highest of 6, against a peer median of +0.0 pp.
  • Over three fiscal years its change of -0.1 pp compares with a peer median of +0.0 pp.
LUNG Competitors Peer median
Gross Margin for LUNG and competitors
Company Period LTM level YoY 3-year change
VXRTVaxart, Inc.LTM Mar 2026100.0% +0.0 pp+0.0 pp
TCRXTScan Therapeutics, Inc.LTM Mar 202692.4% -7.6 pp-27.8 pp
LUNGPulmonx CorporationLTM Mar 202675.5% +2.0 pp-0.1 pp
TELATELA Bio, Inc.LTM Jun 202667.8% +0.5 pp+2.4 pp
HYPRHyperfine, Inc.LTM Mar 202651.2% +5.0 pp+36.5 pp
ASRTAssertio Holdings, Inc.LTM Mar 202644.3% -17.8 pp-43.1 pp
RLMDRelmada Therapeutics, Inc.FY2025— ——
IMUXImmunic, Inc.FY2025— ——
PMVPPMV Pharmaceuticals, Inc.FY2025— ——
ACRVAcrivon Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding LUNG) 67.8%+0.0 pp+0.0 pp

Competitors are the stored peer set for LUNG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.42M53.66M68.68M83.79M90.5M
Cost of Revenue12.79M13.8M17.92M21.79M23.36M
Gross Profit35.63M39.87M50.75M62M67.14M
Gross Margin73.6%74.3%73.9%74.0%74.2%
Research & Development13.06M15.4M18.08M17.57M19.49M
Selling, General & Admin69.87M83.11M94.61M102.14M101.31M
Operating Expenses82.93M98.5M112.69M119.71M120.8M
Depreciation & Amortization867K1.51M1.95M1.59M1.05M
EBITDA(46.62M)(55.99M)(55.09M)(50.79M)(49.17M)
EBITDA Margin-96.3%-104.3%-80.2%-60.6%-54.3%
Operating Income(47.3M)(58.64M)(61.94M)(57.7M)(53.66M)
Operating Margin-97.7%-109.3%-90.2%-68.9%-59.3%
Interest Income400K1.53M5.57M5.06M2.65M
Interest Expense829K1.07M3.23M3.51M3.16M
Other Income / Expenses(1.01M)67K1.66M1.81M286K
Income Before Tax(48.32M)(58.57M)(60.27M)(55.89M)(53.38M)
Pre-Tax Margin-99.8%-109.1%-87.8%-66.7%-59.0%
Income Tax Expense343K353K571K500K626K
Net Income(48.66M)(58.92M)(60.84M)(56.39M)(54M)
Net Margin-100.5%-109.8%-88.6%-67.3%-59.7%
EPS (Basic)(1.35)(1.59)(1.60)(1.44)(1.33)
EPS (Diluted)(1.35)(1.59)(1.60)(1.44)(1.33)
Weighted Avg Shares36.13M37.1M37.97M39.11M40.69M
Weighted Avg Shares (Diluted)36.13M37.1M37.97M39.11M40.69M

Pulmonx Corporation

NASDAQ:LUNG

Intrinsic Alpha fair value

Locked

Current Price

$2.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.